Key result
Targeted genetic sequencing identifies causative variants in ~91% of Chinese familial hypercholesterolemia families.
Observational (n=11)
Answers are grounded in this paper and cite their sources.
Familial hypercholesterolemia (FH) is the first molecularly and clinically characterized genetic disease of lipid metabolism. It is an autosomal dominant disorder with significantly elevated levels of total cholesterol and low density of lipoprotein cholesterol in serum, which would lead to extensive xanthomas and premature coronary heart disease. Mutations in low density lipoprotein receptor ( LDLR ), proprotein convertase subtilisin/kexin type 9 and Apo lipoprotein B - 100 ( APOB ) have been identified to be the underlying cause of this disease. Genetic testing and reports of the mutations in the Chinese population are still limited. In this study, 11 unrelated Chinese FH families were enrolled to detect the candidate gene variants by DNA direct sequencing. We identified 12 mutations (11 in LDLR and one in APOB ) in ten FH families. Three novel LDLR mutations (c.516C>A/p.D172E, c.1720C>A/p.R574S and c.760C>T/p.Q254X) were identified and co-segregated with the affected individuals in the families. Our discoveries not only further supports the significant role of LDLR in FH, but also expands the spectrum of LDLR mutations. These new insights will contribute to the genetic diagnosis and counseling of FH patients.
No takes yet. Share an insight, caveat, or question.
Du et al. (2016) conducted an observational in Familial hypercholesterolemia (n=11). DNA direct sequencing was evaluated on Detection of candidate gene variants. DNA direct sequencing of 11 unrelated Chinese families with familial hypercholesterolemia identified 12 mutations (11 in LDLR and one in APOB) in 10 families, including 3 novel LDLR mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: